Urgent.News

What's breaking now, across hundreds of outlets.

World

Advocates seek action on rare diseases

HEALTH advocates called for government intervention as Filipinos continue to face delayed diagnoses and limited access to specialized treatment 10 years after the enactment of the Rare Disease Act. Dr. Ebner Bon Maceda, director of the Institute of Human Genetics at the University of the Philippines Manila’s National Institutes of Health, said patients still struggle to access specialists and…

Advocates are pushing for government action in the Philippines, where patients with rare diseases continue to face significant obstacles 10 years after the Rare Disease Act was enacted. Dr. Ebner Bon Maceda, director of the University of the Philippines Manila’s National Institutes of Health, highlighted the ongoing struggle patients face in accessing specialists and appropriate treatment, as well as the heavy financial burden they bear.

Maceda emphasized that a decade after the law's passage, the real challenge remains in delivering the support promised to those in need.

Republic Act 10747, the Rare Disease Act, aims to offer patients and their families access to care and treatment. However, advocates argue that implementation is stymied by insufficient government investment and a lack of coordinated action across the healthcare system. The Department of Health’s Integrated Rare Diseases Management Program, which includes a 2022–2026 strategic plan, is intended to guide collaboration among agencies, hospitals, specialists, and patient groups in diagnosing and treating patients.

To truly benefit from the law, patients need well-functioning referral systems, trained health professionals, accessible diagnostic facilities, and sustained funding. In the Philippines, a disease is deemed rare if it affects 1 in 20,000 individuals. The country currently recognizes 159 such diseases. According to a 2020 study by the Institute of Human Genetics, 567 patients with inherited metabolic diseases were identified in its registry from 1999 to 2016.

Notably, 80.6 percent of patients with maple syrup urine disease and 94.7 percent with mucopolysaccharidosis experienced developmental delays or intellectual disability, underscoring the impact of delayed diagnosis and the urgent need for early detection and specialized care.

Patient advocate Juan Magdaraog of the Philippine Society for Orphan Disorders welcomed the release of benefit packages for rare disease patients, expecting an increase in survival rates. However, he stressed that delays in diagnosis and treatment can result in irreversible damage, emphasizing that "for rare disease patients, time is never on their side." Magdaraog also called for the establishment of a rare disease registry and greater patient involvement in policy-making.

Rewritten by urgent.news; may contain errors — check the original.

Read the original at manilatimes.net →

Report a problem with this story

More in World

More from Saturday 21 November →